The aim of our pharmacogenetic study was to identify the effects of fifteen lipid-associated GWAS loci such as rs4846914 (GALNT2), rs11220463 (ST3GAL4), rs881844 (STARD3), rs1689800 (ZNF648), rs12328675 (COBLL1), rs9987289 (PPP1R3B), rs55730499 (LPA), rs3136441 (F2), rs6065906 (PLTP), rs838880 (SCARB1), rs386000 (LILRA3), rs1883025 (ABCA1), rs3764261(CETP), rs217406 (NPC1L1), and rs16942887 (PSKH1) on plasma lipids and CIMT in CAD patients taking rosuvastatin. Here, STARD3 is linked to coronary artery disorder.